1. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011; 7:77–87.
2. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003; 48:3013–22.
3. Strangfeld A, Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during an-ti-TNF therapy. Best Pract Res Clin Rheumatol. 2006; 20:1181–95.
4. Hong MJ, Yoo WH. Biologic agents in rheumatic diseases. Korean J Med. 2012; 82:549–61.
Article
5. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69:88–96.
Article
6. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a dou-ble-blind, placebo-controlled, randomised trial. Lancet. 2008; 371:987–97.
Article
7. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011; 21:10–5.
Article
8. Genentech, Inc. The manual of Actemra (tocilizumab). San Francisco, CA, Genentech: Inc.;2013.
9. Galvão VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015; 3:175–85.
Article
10. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008; 14:109–19.
Article
11. Phoenix G, Das S, Joshi M. Diagnosis and management of cellulitis. BMJ. 2012; 345:e4955.
Article
12. Hirao M, Nampei A, Shi K, Yoshikawa H, Nishimoto N, Hashimoto J. Diagnostic features of mild cellulitis phlegmon in patients with rheumatoid arthritis treated with tocilizumab: a report of two cases. Mod Rheumatol. 2011; 21:673–7.
Article
13. The Korean Society of Infectious Diseases; The Korean Society for Chemotherapy; The Korean Orthopaedic Asso-ciation; The Korean Society of Clinical Microbiology. Korean Dermatological Association. Clinical practice guidelines for soft tissue infections. Infect Chemother. 2012; 44:213–32.
14. Chuang HC, Ho YH, Lay CJ, Wang LS, Tsai YS, Tsai CC. Different clinical characteristics among aeromonas hydro-phila, aeromonas veronii biovar sobria and aeromonas cav-iae monomicrobial bacteremia. J Korean Med Sci. 2011; 26:1415–20.